Eli Lilly and Company (LLY) said, for fiscal 2026, the company projects: earnings per share in a range of $33.50 to $35.00, and revenue of $80 to $83 billion. The company expects continued momentum from Mounjaro and Zepbound worldwide, and growth from key products including Ebglyss, Omvoh, Jaypirca, Inluriyo, and Kisunla.
Fourth quarter net income - reported - was $6.64 billion compared to $4.41 billion, a year ago. EPS increased by 51% to $7.39 on a reported basis. EPS increased by 42% to $7.54 on a non-GAAP basis. The company noted that the results are inclusive of $0.52 of acquired IPR&D charges. Analysts on average expected the company to report profit per share of $6.93, for the quarter. Analysts' estimates typically exclude special items. Revenue increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound. Key Products revenue grew to $13.8 billion, led by Mounjaro and Zepbound.
In pre-market trading on NYSE, Eli Lilly shares are up 7.15 percent to $1,075.49.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.